Last mentioned: Mar 6, 2026
Strategic Update
COSCIENS announces cessation of funding for German subsidiaries and expected insolvency.
Strategic Update
COSCIENS announces cessation of funding for German biopharma subsidiaries.
FDA Type C Meeting
Company meets with FDA to discuss disappointing DETECT trial results and pediatric path forward.
Wuzhou Agreement
Distribution deal signed with Wuzhou Drug International Trading Limited.
FDA Type C Meeting
Regulatory feedback confirms significant hurdles for pediatric expansion.
DETECT Trial Results
Phase 3 trial for Macrilen pediatric indication fails to meet primary endpoints.
DETECT Trial Results
Phase 3 trial for pediatric indication yields disappointing results.
Wuzhou Distribution Deal
COSCIENS signs distribution agreement with Wuzhou Drug International Trading Limited.
COSCIENS Biopharma Inc. has announced a definitive strategic shift by ceasing all funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The decision triggers a structured insolvency process for the units following the failure of a Phase 3 pediatric trial for its flagship diagnostic, Macrilen.
COSCIENS Biopharma Inc. (TSX: CSCI) has announced a strategic cessation of funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, effectively triggering an insolvency process. This decision follows a critical failure in the Phase 3 DETECT trial for Macrilen’s pediatric indication and a subsequent setback in FDA negotiations.